56119-60-9 Usage
Uses
Used in Organic Synthesis:
Di-tert-butylChlorophosphate is used as a reagent in organic synthesis for its ability to facilitate various chemical reactions. Its organophosphate structure makes it a versatile component in the creation of different organic compounds.
Used in Chemical Intermediates:
In the chemical industry, di-tert-butylChlorophosphate is employed as a chemical intermediate, contributing to the production of a range of end products. Its role in intermediate stages of chemical processes is crucial for the synthesis of specific target molecules.
Used in Research and Development:
Due to its unique properties and reactivity, di-tert-butylChlorophosphate is also utilized in research and development settings. It aids scientists in exploring new chemical pathways and developing innovative applications in various fields of chemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 56119-60-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,6,1,1 and 9 respectively; the second part has 2 digits, 6 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 56119-60:
(7*5)+(6*6)+(5*1)+(4*1)+(3*9)+(2*6)+(1*0)=119
119 % 10 = 9
So 56119-60-9 is a valid CAS Registry Number.
InChI:InChI=1/C8H18ClO3P/c1-7(2,3)11-13(9,10)12-8(4,5)6/h1-6H3
56119-60-9Relevant academic research and scientific papers
SCALABLE SYNTHETIC ROUTE FOR PSILOCIN AND PSILOCYBIN
-
Paragraph 00178-00179; 00191, (2022/02/05)
The present application relates to cost-effective, practical and scalable synthetic routes for the syntheses for psilocybin (Formula I) and its major metabolite psilocybin (Formula II) and their pharmaceutically acceptable salts. These compounds are useful for the treatment or prevention of mental health disorders, such as major depressive disorder, anxiety and addiction disorders, among others CNS disorders.
HYDROXAMIC ACID DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS
-
Page/Page column 84, (2010/04/25)
The invention relates to a compound of formula (I): or a pharmaceutically acceptable salt thereof, thereof, wherein: G is a group of formula (II); and pharmaceutically acceptable salts, prodrugs, hydrates, or solvates, thereof, wherein A, B. L1-L4 A, B, R1-R4 and m are as defined herein. The invention also relates to pharmaceutical compositions comprising the compounds of formula (I) and their use in treating a bacterial infection.